PTSD in military and veteran populations¶
TL;DR — Military and veteran cohorts contribute disproportionately to PTSD treatment evidence, especially for PE, CPT, prazosin and MDMA, but they are not proxies for all PTSD. Service era, combat role, military sexual trauma, moral injury, TBI, chronic pain, disability systems and access to VA/DoD care alter case mix. The 304-person prazosin re-test and 916-person CPT-versus-PE dropout analysis are informative precisely within veteran systems (Raskind 2018, PMID 29414272) (Harper 2026, PMID 41926191). Meta-regression found larger exposure-therapy effects in civilian/refugee than military studies, a study-level signal requiring patient-level confirmation (McLean 2022, PMID 34954460).
Exposure and selection¶
Deployment and combat exposure vary by role, era and branch; veterans are also selected survivors of occupational and healthcare systems, and the population studied changes with the historical moment (Jones 2019, PMID 31184277). Prevalence therefore requires an explicit denominator and an explicit age band: PTSD prevalence in older US military veterans is reported separately from the general veteran population (Little 2018, PMID 29609900), and PTSD in older adults raises distinct measurement and course questions (Pless Kaiser 2019, PMID 30422749). Against a US lifetime population prevalence of 6.1–8.3%, veteran status is one of the two subgroups (with women) in which prevalence is consistently higher (Flesaker 2026, PMID 42089634).
Clinical phenotype¶
Repeated exposure, moral injury, bereavement, sleep disturbance, pain, TBI and substance use can co-occur. None should be automatically folded into PTSD severity (Griffin 2019, PMID 30688367) (Karimov-Zwienenberg 2024, PMID 39213321).
Treatment evidence¶
PE and CPT have large veteran evidence bases, but completion and functional recovery remain imperfect: in the largest randomized comparison, dropout was 52.31% in PE and 45.77% in CPT (Harper 2026, PMID 41926191), and across pooled individual participant data from 25 trauma-focused CBT trials, dropout was 42% among military personnel and veterans against 23% among civilians (RR 2.37) (Wright 2024, PMID 39537555) (Lewis 2020, PMID 32284821). Retention, not efficacy, is the distinctive military-population problem. Partner-involved treatment addresses relational outcomes as well as PTSD, though comparative samples are small (Monson 2024, PMID 38590124).
Prazosin lesson¶
Small positive veteran studies were followed by a large veteran null study; ‘veteran PTSD’ is itself heterogeneous (Raskind 2003, PMID 12562588) (Raskind 2007, PMID 17069768) (Raskind 2018, PMID 29414272).
Generalisability¶
Study-level differences by military versus civilian setting may reflect sex distribution, trauma type, chronicity, comorbidity, compensation context, therapist system or true effect modification (McLean 2022, PMID 34954460).
Moral injury¶
Potentially morally injurious experiences correlate with PTSD, guilt, shame, depression and spiritual distress but moral injury lacks a consensus diagnosis or gold-standard outcome (Griffin 2019, PMID 30688367).
Systems¶
VA/DoD evidence and infrastructure support dissemination unavailable in many civilian settings. Effectiveness depends on referral, wait time, fidelity, choice and continuity.
Quantitative anchors¶
| Measure | Estimate | Population/method | Source |
|---|---|---|---|
| Prazosin PACT | n=304; 13 VA centres | Chronic PTSD + nightmares | (Raskind 2018, PMID 29414272) |
| CPT vs PE dropout | n=916; 79.9% male | US veterans | (Harper 2026, PMID 41926191) |
| Exposure meta-analysis | 65 articles; n=4,929 | Smaller study-level effects in military samples | (McLean 2022, PMID 34954460) |
| MDMA phase 2 | dose-response RCT | Veterans, firefighters, police | (Mithoefer 2018, PMID 29728331) |
| Conjoint vs PE | 32 dyads | Service members/veterans + partners | (Monson 2024, PMID 38590124) |
| TF-CBT dropout, military vs civilian | 42% vs 23% (RR 2.37) | IPD pool of 25 trials; n=823 | (Wright 2024, PMID 39537555) |
| US lifetime prevalence context | 6.1–8.3%; higher in veterans and women | Population review | (Flesaker 2026, PMID 42089634) |
| PE vs CPT dropout | PE 52.31% vs CPT 45.77% | n=916 US veterans | (Harper 2026, PMID 41926191) |
Evidence ledger¶
The ledger lists the live-retrieved records used to bound this page. Inclusion does not make every record equally probative; design, population and comparator remain decisive.
| PMID | Year | Evidence contribution | Scope caution |
|---|---|---|---|
| 30422749 | 2019 | Posttraumatic Stress Disorder in Older Adults: A Conceptual Review. | Synthesis: preserve included-population and certainty limits |
| 31184277 | 2019 | PTSD in an era of uncertainty and challenge. | PTSD-specific record; inspect design and population |
| 29609900 | 2018 | Prevalence of Mental Health Disorders in Geriatric U.S. Military Veterans. | PTSD-specific record; inspect design and population |
| 27533475 | 2016 | Lessons learned in a clinical trial for military sexual trauma-related posttraumatic stress disorder. | PTSD-specific record; inspect design and population |
| 31043106 | 2019 | Treatment of military-related post-traumatic stress disorder: challenges, innovations, and the way forward. | PTSD-specific record; inspect design and population |
| 38651819 | 2024 | Prevalence of Complex Post-Traumatic Stress Disorder in Serving Military and Veteran Populations: A Systematic Review. | Synthesis: preserve included-population and certainty limits |
| 37500255 | 2023 | Psychiatric Issues in Women Veterans. | PTSD-specific record; inspect design and population |
| 35705259 | 2024 | Addressing moral injury in the military. | PTSD-specific record; inspect design and population |
| 23584106 | 2012 | Alcohol and stress in the military. | PTSD-specific record; inspect design and population |
| 33524199 | 2021 | Posttraumatic Stress Disorder Treatment Dropout Among Military and Veteran Populations: A Systematic Review and Meta-Analysis. | Synthesis: preserve included-population and certainty limits |
| 39422975 | 2024 | Traumatic brain injury rehabilitation for warfighters with post-traumatic stress. | PTSD-specific record; inspect design and population |
| 32005353 | 2020 | Posttraumatic Stress Disorder, Traumatic Brain Injury, Sleep, and Performance in Military Personnel. | PTSD-specific record; inspect design and population |
| 34531106 | 2022 | Illness-induced post-traumatic stress disorder among Canadian Armed Forces Members and Veterans. | PTSD-specific record; inspect design and population |
| 31198655 | 2018 | Co-Occurring Post-Traumatic Stress Disorder and Alcohol Use Disorder in U.S. Military and Veteran Populations. | PTSD-specific record; inspect design and population |
| 36252350 | 2022 | Prevalence and predictors of anxiety disorder courses in the Canadian Armed Forces. | Pooled/cross-disorder: use only an explicit PTSD stratum |
| 25469959 | 2014 | Treatment for posttraumatic stress disorder in military and veteran populations: final assessment. | PTSD-specific record; inspect design and population |
| 34855539 | 2023 | Complementary and Integrative Health Interventions for Insomnia in Veterans and Military Populations. | PTSD-specific record; inspect design and population |
| 25222535 | 2014 | Chapter 1 posttraumatic stress disorder: a view from the operating theater. | PTSD-specific record; inspect design and population |
| 29414272 | 2018 | Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. | PTSD-specific record; inspect design and population |
| 12562588 | 2003 | Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. | PTSD-specific record; inspect design and population |
| 17069768 | 2007 | A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. | PTSD-specific record; inspect design and population |
| 41926191 | 2026 | Comparing dropout from cognitive processing therapy versus prolonged exposure: Results from a randomized clinical trial. | PTSD-specific record; inspect design and population |
| 34954460 | 2022 | Exposure therapy for PTSD: A meta-analysis. | Synthesis: preserve included-population and certainty limits |
| 29728331 | 2018 | 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. | PTSD-specific record; inspect design and population |
| 38590124 | 2024 | Cognitive-behavioural conjoint therapy versus prolonged exposure for PTSD in military service members and veterans: results and lessons from a randomized controlled trial. | PTSD-specific record; inspect design and population |
| 30688367 | 2019 | Moral Injury: An Integrative Review. | Synthesis: preserve included-population and certainty limits |
| 39213321 | 2024 | Childhood trauma, PTSD/CPTSD and chronic pain: A systematic review. | Synthesis: preserve included-population and certainty limits |
| 32284821 | 2020 | Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis. | Synthesis: preserve included-population and certainty limits |
| 39537555 | 2024 | Predictors of study dropout in cognitive-behavioural therapy with a trauma focus for post-traumatic stress disorder in adults: An individual participant data meta-analysis. | Military status is a study-level and participant-level covariate here |
| 42089634 | 2026 | State of the Science: The epidemiology of posttraumatic stress disorder. | Review of population estimates |
Interpretation guardrails¶
- Trauma exposure, post-traumatic symptoms, acute stress disorder, DSM-5 PTSD, ICD-11 PTSD and ICD-11 complex PTSD are not interchangeable populations.
- A mixed-anxiety or transdiagnostic estimate is labelled as such; only a source’s PTSD stratum can be treated as a PTSD effect.
- Comorbid depression is measured separately and cross-linked to the depression condition; it is not absorbed into PTSD.
- Waitlist, treatment-as-usual, attention control and active treatment answer different causal questions.
- Registration, statistical significance and diagnostic loss do not respectively prove completion, clinical importance or functional recovery.
- This page synthesizes research and does not provide individual medical advice.
Minimum extraction frame for studies on this topic¶
| Field | What must be retained | Why it changes interpretation |
|---|---|---|
| Diagnostic system | DSM version, ICD version, full/subthreshold | Case mix is not interchangeable |
| Diagnostic method | Structured interview, clinician judgment, self-report cutoff | Screening is not diagnosis |
| Index trauma | Type, timing, repetition, direct/indirect/occupational | Conditional risk and phenotype differ |
| Population | Civilian, veteran, refugee, child/adolescent, mixed | Transportability is empirical |
| Baseline severity | Mean, SD, range and exclusion threshold | Ceiling and floor effects alter change |
| CPTSD status | ITQ/ICD-11 definition and DSO score | Complexity cannot be inferred from trauma count |
| Comorbidity | Depression, GAD, SUD, pain, TBI measured separately | Shared symptoms can distort effects |
| Comparator | Waitlist, usual care, attention, active treatment | The estimand changes with comparator |
| Treatment dose | Sessions offered/attended, duration, homework | Assignment is not exposure |
| Outcome | Symptoms, diagnosis, response, function, sleep | Outcomes are not interchangeable |
| Time point | End point and prespecified follow-up windows | Acute benefit may not persist |
| Missing data | Denominator, reasons, imputation and estimand | Attrition can bias rank and magnitude |
| Adverse events | Definitions, ascertainment and arm-level counts | Absence of reporting is not absence of harm |
| Therapist/context | Training, fidelity, allegiance, setting | Delivery is part of the intervention |
| Funding/conflicts | Sponsor role and analytic independence | Especially material for proprietary packages |
Claims this page does not make¶
- It does not infer PTSD from trauma exposure alone.
- It does not treat a self-report cutoff as equivalent to a structured diagnosis.
- It does not convert a pooled anxiety-disorder effect into a PTSD effect.
- It does not convert a depression outcome in a comorbid sample into a PTSD outcome.
- It does not infer superiority from a statistically significant within-group change.
- It does not infer equivalence from a non-significant between-group test.
- It does not infer effectiveness from trial registration or mechanistic plausibility.
- It does not assume military, civilian, refugee and pediatric estimates transport unchanged.
- It does not average conflicting estimates that use different definitions.
- It does not treat lack of adverse-event reporting as evidence of safety.
Evidence-updating triggers¶
| Trigger | Required response |
|---|---|
| New diagnostic revision | Recalculate which populations prior estimates represent |
| New head-to-head RCT | Compare against active treatment, not only waitlist |
| New individual-participant synthesis | Revisit effect modifiers and transportability |
| Registry status change | Verify results and linked publication before changing conclusions |
| Guideline update | Separate evidence review from panel recommendation |
| Regulatory decision | Record decision date and source; do not infer from efficacy papers |
| Safety signal | Re-extract denominator, ascertainment and exposure time by arm |
| Contradictory replication | Display estimates side by side; do not average definitions |
Evidence updates should preserve the prior estimate and explain why the new study changes—or does not change—the inference.
Open questions¶
- Which treatment-effect modifiers replicate within individual-participant military/civilian comparisons? (McLean 2022, PMID 34954460)
- How should PTSD, TBI, pain and moral injury be sequenced or integrated? (Karimov-Zwienenberg 2024, PMID 39213321) (Griffin 2019, PMID 30688367)
- Which system changes reduce veteran dropout without diluting treatment fidelity? (Harper 2026, PMID 41926191)
Related pages¶
- prolonged-exposure — major veteran treatment.
- cognitive-processing-therapy — major veteran treatment.
- moral-injury — related construct.
- comorbidity — TBI, pain and substance use.
References¶
- Pless Kaiser A, et al. Posttraumatic Stress Disorder in Older Adults: A Conceptual Review. Clin Gerontol. 2019;42(4):359-376. PMID 30422749
- Jones E PTSD in an era of uncertainty and challenge. Int Rev Psychiatry. 2019;31(1):1-2. PMID 31184277
- Little JT Prevalence of Mental Health Disorders in Geriatric U.S. Military Veterans. Am J Geriatr Psychiatry. 2018;26(5):546-547. PMID 29609900
- Surís A, et al. Lessons learned in a clinical trial for military sexual trauma-related posttraumatic stress disorder. J Rehabil Res Dev. 2016;53(4):vii-x. PMID 27533475
- Forbes D, et al. Treatment of military-related post-traumatic stress disorder: challenges, innovations, and the way forward. Int Rev Psychiatry. 2019;31(1):95-110. PMID 31043106
- Grinsill R, et al. Prevalence of Complex Post-Traumatic Stress Disorder in Serving Military and Veteran Populations: A Systematic Review. Trauma Violence Abuse. 2024;25(4):3377-3387. PMID 38651819
- Alpert E, et al. Psychiatric Issues in Women Veterans. Psychiatr Clin North Am. 2023;46(3):621-633. PMID 37500255
- Phelps AJ, et al. Addressing moral injury in the military. BMJ Mil Health. 2024;170(1):51-55. PMID 35705259
- Schumm JA, et al. Alcohol and stress in the military. Alcohol Res. 2012;34(4):401-7. PMID 23584106
- Edwards-Stewart A, et al. Posttraumatic Stress Disorder Treatment Dropout Among Military and Veteran Populations: A Systematic Review and Meta-Analysis. J Trauma Stress. 2021;34(4):808-818. PMID 33524199
- Babakhanyan I, et al. Traumatic brain injury rehabilitation for warfighters with post-traumatic stress. NeuroRehabilitation. 2024;55(3):295-302. PMID 39422975
- Moore BA, et al. Posttraumatic Stress Disorder, Traumatic Brain Injury, Sleep, and Performance in Military Personnel. Sleep Med Clin. 2020;15(1):87-100. PMID 32005353
- Gill GK, et al. Illness-induced post-traumatic stress disorder among Canadian Armed Forces Members and Veterans. J Anxiety Disord. 2022;86:102472. PMID 34531106
- Dworkin ER, et al. Co-Occurring Post-Traumatic Stress Disorder and Alcohol Use Disorder in U.S. Military and Veteran Populations. Alcohol Res. 2018;39(2):161-169. PMID 31198655
- Pankratz L, et al. Prevalence and predictors of anxiety disorder courses in the Canadian Armed Forces. J Anxiety Disord. 2022;92:102612. PMID 36252350
- Anonymous Treatment for posttraumatic stress disorder in military and veteran populations: final assessment. Mil Med. 2014;179(12):1401-3. PMID 25469959
- Staples JK, et al. Complementary and Integrative Health Interventions for Insomnia in Veterans and Military Populations. Psychol Rep. 2023;126(1):52-65. PMID 34855539
- Vacchiano CA, et al. Chapter 1 posttraumatic stress disorder: a view from the operating theater. Annu Rev Nurs Res. 2014;32:1-23. PMID 25222535
- Raskind MA, et al. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. N Engl J Med. 2018;378(6):507-517. PMID 29414272
- Raskind MA, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371-3. PMID 12562588
- Raskind MA, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928-34. PMID 17069768
- Harper KL, et al. Comparing dropout from cognitive processing therapy versus prolonged exposure: Results from a randomized clinical trial. J Consult Clin Psychol. 2026;94(3):140-150. PMID 41926191
- McLean CP, et al. Exposure therapy for PTSD: A meta-analysis. Clin Psychol Rev. 2022;91:102115. PMID 34954460
- Mithoefer MC, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5(6):486-497. PMID 29728331
- Monson CM, et al. Cognitive-behavioural conjoint therapy versus prolonged exposure for PTSD in military service members and veterans: results and lessons from a randomized controlled trial. Eur J Psychotraumatol. 2024;15(1):2330305. PMID 38590124
- Griffin BJ, et al. Moral Injury: An Integrative Review. J Trauma Stress. 2019;32(3):350-362. PMID 30688367
- Karimov-Zwienenberg M, et al. Childhood trauma, PTSD/CPTSD and chronic pain: A systematic review. PLoS One. 2024;19(8):e0309332. PMID 39213321
- Lewis C, et al. Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020;11(1):1729633. PMID 32284821
- Wright S, et al. Predictors of study dropout in cognitive-behavioural therapy with a trauma focus for post-traumatic stress disorder in adults: An individual participant data meta-analysis. BMJ Ment Health. 2024;27(1):e301159. PMID 39537555
- Flesaker M, et al. State of the Science: The epidemiology of posttraumatic stress disorder. J Trauma Stress. 2026;39(3):353-363. PMID 42089634